Ligand Pharmaceuticals Incorporated - Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated (LGND) has an Asset Resilience Ratio of 43.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Ligand Pharmaceuticals Incorporated's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Ligand Pharmaceuticals Incorporated to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ligand Pharmaceuticals Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ligand Pharmaceuticals Incorporated market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $664.33 Million | 43.36% |
| Total Liquid Assets | $664.33 Million | 43.36% |
Asset Resilience Insights
- Very High Liquidity: Ligand Pharmaceuticals Incorporated maintains exceptional liquid asset reserves at 43.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ligand Pharmaceuticals Incorporated Industry Peers by Asset Resilience Ratio
Compare Ligand Pharmaceuticals Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Ligand Pharmaceuticals Incorporated (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Ligand Pharmaceuticals Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.79% | $558.59 Million | $1.56 Billion | +16.27pp |
| 2024-12-31 | 19.52% | $183.86 Million | $941.77 Million | +0.80pp |
| 2023-12-31 | 18.72% | $147.35 Million | $787.22 Million | -3.16pp |
| 2022-12-31 | 21.88% | $166.86 Million | $762.67 Million | -2.90pp |
| 2021-12-31 | 24.78% | $321.59 Million | $1.30 Billion | -1.90pp |
| 2020-12-31 | 26.69% | $363.57 Million | $1.36 Billion | -40.09pp |
| 2019-12-31 | 66.78% | $998.32 Million | $1.49 Billion | +63.12pp |
| 2018-12-31 | 3.66% | $46.19 Million | $1.26 Billion | -23.32pp |
| 2017-12-31 | 26.98% | $181.04 Million | $671.02 Million | +6.65pp |
| 2016-12-31 | 20.33% | $122.30 Million | $601.59 Million | +1.08pp |
| 2015-12-31 | 19.25% | $102.79 Million | $533.93 Million | +16.49pp |
| 2014-12-31 | 2.76% | $7.13 Million | $258.03 Million | -1.38pp |
| 2013-12-31 | 4.14% | $4.34 Million | $104.71 Million | +1.49pp |
| 2012-12-31 | 2.65% | $2.77 Million | $104.26 Million | -5.52pp |
| 2011-12-31 | 8.17% | $10.00 Million | $122.35 Million | -17.44pp |
| 2010-12-31 | 25.61% | $19.35 Million | $75.56 Million | -7.11pp |
| 2009-12-31 | 32.72% | $37.20 Million | $113.70 Million | +2.44pp |
| 2008-12-31 | 30.28% | $51.92 Million | $171.45 Million | +20.13pp |
| 2007-12-31 | 10.15% | $17.60 Million | $173.28 Million | +6.03pp |
| 2006-12-31 | 4.12% | $13.45 Million | $326.05 Million | -2.29pp |
| 2005-12-31 | 6.41% | $20.17 Million | $314.62 Million | +0.34pp |
| 2004-12-31 | 6.07% | $20.18 Million | $332.47 Million | -7.21pp |
| 2003-12-31 | 13.28% | $40.00 Million | $301.25 Million | +5.21pp |
| 2002-12-31 | 8.07% | $21.82 Million | $270.61 Million | -6.36pp |
| 2001-12-31 | 14.43% | $16.95 Million | $117.47 Million | +1.70pp |
| 2000-12-31 | 12.73% | $14.44 Million | $113.42 Million | -0.12pp |
| 1999-12-31 | 12.85% | $17.30 Million | $134.60 Million | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more